

# Analyst

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

## Aminolevulinic acid with gold nanoparticles: a novel theranostic agent for atherosclerosis

Karina de Oliveira Gonçalves<sup>a</sup>, Monica Nascimento da Silva<sup>a</sup>, Letícia Bonfante Sicchieri<sup>b</sup>, Flávia Rodrigues de Oliveira Silva<sup>c</sup>, Ricardo Almeida de Matos<sup>a</sup>, and Lilia Coronato Courrol<sup>a,b</sup>

Received (in XXX, XXX) Xth XXXXXXXXXX 20XX, Accepted Xth XXXXXXXXXX 20XX

DOI: 10.1039/b000000x

In this study, 5-Aminolevulinic acid (ALA) gold nanoparticles (ALA:AuNPs) functionalized with polyethylene glycol (PEG) were synthesized and administered to rabbits to evaluate its use in clinical practice as theranostic agent for atherosclerosis. This was done by measuring the porphyrin fluorescence extracted for the rabbit's blood and feces. An increase in the blood and feces porphyrin emission after ALA:AuNPs administration suggests that ALA was incorporated by the gold nanoparticles, its structure was preserved, and a rapid conversion into endogenous porphyrins occurred, overloading the synthetic pathway that lead to the protoporphyrin IX (PPIX) accumulation. This finding indicated that this method can aid in the early diagnosis and therapy of atherosclerosis with high sensitivity.

### A. Introduction

Atherosclerosis, or hardening of the arteries, is the main cause of heart attacks, strokes, and peripheral vascular diseases. It is characterized by endothelial cell injury, lipoprotein deposition, inflammation reaction, cell proliferation, vascular remodeling, plaque formation and expansion and rupture, culminating with thrombosis of the vessel<sup>1</sup>.

Atherosclerotic cardiovascular disease and cancer are the leading causes of death in the world. Atherogenesis and neoplasia have some common points such as oxidative stress and the cellular damage that results from angiogenesis, and accumulation of protoporphyrin IX<sup>2</sup>. The shared features of atherosclerosis and cancer justify similar novel approaches to diagnosis and therapy.

The theranostic agents are capable of providing both a diagnostic as well as a therapeutic function<sup>3</sup>. A significant growth in the field of theranostics for cancer and inflammatory diseases, as atherosclerosis, has occurred in the last decade<sup>4,5</sup>. Although light-mediated theranostics are selective they cause significant tissue damage and induce inflammatory reactions, which can lead to disease recurrence<sup>6</sup>.

Gold nanoparticles (AuNPs) are emerging promising agents for cancer and atherosclerosis theranostics<sup>3,4</sup>. Gold nanoparticles exhibit unique physicochemical properties including surface plasmon resonance effect, good light scattering, absorption capability, small size, high atomic number, biocompatibility and the ability to bind targeting agents, implying that they have potential as contrast agents<sup>5</sup>. In addition, the combined of AuNPs and diffusion reflection<sup>6</sup> (DR) presents a method to detect cancer and atherosclerosis at its early stages<sup>7</sup>. The unique surface plasmon resonance feature of AuNPs makes them candidate materials in photothermal therapy (PTT)<sup>8</sup>. The AuNPs can act as energy transducers, converting light into heat and selective macrophage depletion<sup>8</sup>. Compared with conventional drug delivery, such a treatment is active only within

the limited illumination area, therefore minimizing normal tissue damage<sup>7</sup>.

The use of gold nanoparticles as carriers of photosensitizers is a very promising approach for photodynamic therapy (PDT), a noninvasive treatment modality for atherosclerosis and cancers<sup>8</sup>. PDT involves the administration of photosensitizer (PS) molecules that binds to the atherosclerosis plaques<sup>9</sup> (or cancerous cells), and subsequently, under irradiation with appropriate light, produces reactive oxygen species (ROS) that chemically destroy the plaques. 5-Aminolevulinic acid (ALA)-based PDT is gaining increasing attention in medicine<sup>10</sup>. The external addition of ALA results in enhanced synthesis of protoporphyrin IX (PPIX) by the cellular heme biosynthetic pathway. PDT mediated by ALA has low dark toxicity to cells, rapid clearance from the body (24–48 h) and rapid conversion into PPIX through the heme cycle<sup>15</sup>. It was demonstrated that ALA-derived PPIX preferentially accumulates in atherosclerotic plaques, and its fluorescence intensity is positively correlated with plaque macrophage content<sup>8</sup>. The use of AuNPs as the vehicle for 5-ALA delivery represents a promising approach, especially with the recent demonstration that immobilization of PS on the particle surface is better for ROS formation<sup>11,12</sup>.

Another possible therapy use of ALA is sonodynamic therapy<sup>13,14</sup>, which realized the strategy of reducing the infiltration of macrophages in atherosclerotic plaque, and might be a good treatment for atherosclerosis<sup>15</sup>.

In this study, ALA gold nanoparticles (ALA:AuNPs) functionalized with polyethylene glycol (PEG) were synthesized and administered to rabbits to evaluate its use in clinical practice as theranostic agent for atherosclerosis. This was done by measuring the PPIX fluorescence extracted for the rabbit's blood and feces.

## B. Materials and Methods

### ALA:AuNPs solution

Tetrachloroauric acid (HAuCl<sub>4</sub>) and 5-Aminolevulinic acid hydrochloride ~98% (A3785) were purchased from Sigma-Aldrich. To prepare ALA Gold Nanoparticles (ALA:AuNPs) solutions, ~21 mg of HAuCl<sub>4</sub> were mixed with ~83 mg of ALA in 200 mL of distilled water at 20°C. The process was accompanied by vigorous stirring for 5 minutes, and the resulting solution was exposed to a 150-watt xenon lamp for 2 minutes.

The solutions UV-Vis absorption spectra were measured by a Varian Cary 17D spectrophotometer, using 1-cm quartz cells.

Transmission Electron micrographies were obtained from a Jeol (Zeiss, Germany) transmission electron microscope (TEM), with images captured by a MegaView III camera and processed by the software ITEM (Universal TEM Imaging Platform (Olympus Soft Imaging Solutions GmbH, Germany). For this, a drop of gold nanoparticles dispersed in distilled water was placed onto a carbon-coated copper grid, the excess liquid was removed using a paper wick, and the deposit was dried in air prior to imaging.

### Animal experimentation

A total of 16 adult white male rabbits (New Zealand species *Oryctolagus cuniculus*, weighing 2.3 ± 0.1 kg, and ~3.5 months of age) were divided into the groups shown in table 1:

**Table 1:** Experimental Groups.

Groups	Characteristics
<b>CG</b> <b>Control Group:</b>	4 animals Normal diet
<b>EG</b> <b>Experimental Group</b>	3 animals Diet containing 1% cholesterol (Sigma Aldrich)
<b>CGALA</b> <b>Control Group and ALA</b>	3 animals Normal diet and oral ALA administration
<b>EGALA</b> <b>Experimental Group and ALA</b>	3 animals Diet containing 1% cholesterol (Sigma Aldrich) diluted in chloroform and oral ALA administration
<b>EGALAAu</b> <b>Experimental Group and ALA:AuNPs</b>	3 animals Diet containing 1% cholesterol (Sigma Aldrich) diluted in chloroform and oral ALA:AuNPs administration

The animals were individually housed in a controlled environment that was maintained at 19°C; food and water were provided *ad libitum*. Blood samples were extracted in beginning and after 34 days and 60 days, and feces samples were collected after 33 days. After 60 days, the animals were anesthetized by an injection of ketamine and xylazine and then euthanized by a heart injection of 1 mL of potassium chloride, according to the American Veterinary Medical Association guidelines for euthanasia.

The Ethics Committee of UNIFESP approved the protocol of this study (CEUA N. 1147091113).

### Biochemical analyses of Blood Serum

After overnight fasting, blood was drawn from the marginal ear vein at the baseline time point. The blood samples were stored on ice for 2 h and centrifuged (3000 rpm, 10 min, 4 °C) to obtain serum. The total cholesterol (TC), high-density lipoprotein HDL-C, low-density cholesterol (LDL-C) and glucose levels in the serum samples were assessed using an enzymatic colorimetric assay (Labtest Diagnostic S.A) with an automatic biochemical analyzer.

### Porphyrin extraction

Three parts by volume of analytical grade acetone were added to one part of the total blood or macerated feces, and the resulting combination was well mixed. This mixture was centrifuged at 4000 rpm for 15 min. The clear supernatant of the mixture was stored in a clean tube, and spectrofluorimetric analyses were performed on the same day.

### Administration of ALA solution

Solutions of ALA were freshly prepared at a concentration of 60 mg/kg and 100mg/mL in physiological serum. The pH of the solutions was adjusted to 6.8 using NaOH.

The ALA:AuNPs were prepared in a concentration of ~57.74 mg/kg. ALA and ALA:AuNPs were orally administrated to the animals with syringes (~3.75 mL).

The blood was collected before and ~4 hours after ALA and ALAAu administration, and also before and 34 and 60 days after introduction of the diet procedure.

### Artery excision and histological analysis

The rabbit's arteries were excised and washed in PBS. Cryosections of the aortic arch specimens were cut in the vertical plane to a 10 μm thickness on a cryostat, mounted on glass slides and stained with hematoxylin and eosin. The images were obtained using a Leica DMI6000 CS fluorescence microscope, Leica DFC360FX digital video camera and Leica AF6000 software (Laboratory of Applied Biomedical Optics at UNIFESP).

### Fluorescence spectral analyses

The blood and feces extracted PPIX solutions emission spectra were obtained by exciting the samples at 405 nm using a 1 mm optical path cuvette (Hellma). The sample fluorescence was measured from 550–750 nm using a Horiba Jobin Yvon Fluorolog 3 Fluorimeter ((Laboratory of Applied Biomedical Optics at UNIFESP).

### Statistical Analysis

The data are expressed as the mean ± standard error of the mean (S.E.M.). The statistical comparisons among the groups were performed using a one-way analysis of variance (ANOVA). Probability values of p < 0.05 were considered statistically significant. All of the experiments were performed independently and repeated a minimum of three times. The GraphPad Prism 5 package was used.

The effect size<sup>16</sup>, the standardized mean difference between the two groups, was determined by equation 1:

$$\text{Effect Size} = \left[ \frac{\text{Mean of EGALA or EGALAAu} - \text{Mean of CG or CGALA}}{\text{Standard Deviation}} \right] \quad [1]$$

The Standard Deviation (pooled)<sup>16</sup> was estimate as an average of the standard deviations of the experimental and control groups and were calculated by equation 2:

$$SD_{\text{Spooled}} = \sqrt{\frac{(N_E - 1)SD_E^2 + (N_C - 1)SD_C^2}{N_E + N_C - 2}} \quad [2]$$

Where  $N_E$  and  $N_C$  are the numbers in the experimental and control groups, respectively, and  $SD_E$  and  $SD_C$  are their standard deviations.

Power analysis was performed by Statistics/Power and Sample Size: PSS\_tTest 2 from OriginPro8.

## C. Results and Discussion

### C.1) Synthesis and characterization of ALA gold

#### nanoparticles (ALA:AuNPs)

The absorbance of the gold colloidal solutions was measured for the solutions prepared with Chloroauric acid and Polyethylene glycol (PEG). According to the literature, PEGylation leads to the sufficient stability of the material in aqueous media and strong resistance of the binding against various biomolecules<sup>17</sup>. The results are shown in figure 1. Before Xenon illumination, an absorption band at approximately 310 nm, characteristic of ALA, is observed. During the Xe light exposure the solution color changes from colorless to purple (Figure 2a), and after the illumination ends, an absorption peak at approximately 540 nm appears due to the SPR (surface plasmon resonance) effect, indicating the formation of gold nanoparticles<sup>18</sup>. Changing the solution pH from ~3.0 to ~7.0, the absorption peak is blue-shifted and narrowed (figure 1), and the solution color becomes reddish (figure 2b). The blue shift observed in the spectra can be attributed to the gold nanoparticles size reduction.

The Zeta potential of the solutions was measured, and increasing the solution pH from ~5.0 to ~8.0, changes its value from ~10 to ~40 mV was observed. Thus, greater stability is achieved with the basic pH. The increase in pH enables nanoparticles stabilization against agglomeration and precipitation.

Transmission Electron Microscopy was used to characterize the size, shape and morphology of the synthesized ALA:AuNPs, and the micrographies of the synthesized particles before and after pH changing are shown in figure 3. The ALA:AuNPs after pH correction are nearly spherical with sizes ranging from 5 to 40 nm, as observed in figure 5c.

The synthesis of the nanoparticles is possible because the light promotes the reduction of gold ions ( $\text{Au}^{3+}$ ) to metallic gold ( $\text{Au}^0$ ) (in ALA/ Tetrachloroauric acid solution) and the ALA avoids their agglomeration, stabilizing the colloidal suspension<sup>19</sup>. The use of Xenon light is important to catalyze this reduction, since the ALA by itself does not promote efficient reduction of gold. The increase in the pH recovers the ALA structure, enabling nanoparticle stabilization against agglomeration and precipitation.

**Figure 1.** Optical absorption spectra of gold nanoparticles formed with illumination for 1 minute by a Xe lamp. ALA+PEG ( $\text{HAuCl}_4 = 0.02074\text{g} + \text{ALA} = 0.08332\text{g} + \text{PEG} = 0.02844\text{g}$  in

200 ml Milli-Q  $\text{H}_2\text{O}$ ); ALA+PEG+Xe (ALA+PEG and 2 minutes of Xe lighth irradiation); ALA+PEG+Xe+pH (ALA +PEG +Xe and pH of solution adjusted to 7.2).

**Figure 2.** Color of a gold colloidal suspension: a) before (left) and after (right) illumination with white light from a Xe-lamp for 1 minute and b) after change pH from ~3.0 to 7.0.

**Figure 3.** TEM images of synthesized ALA:AuNPs: a) ALA+PEG+Xe ( $\text{HAuCl}_4 = 0,02074\text{g} + \text{ALA} = 0,08332\text{g} + \text{PEG} = 0,02844\text{g}$  in 200 ml Mili-Q  $\text{H}_2\text{O}$  and 2 minutes of Xe lighth irradiation); b) ALA + PEG + Xe + pH (ALA +PEG +Xe and pH of solution adjusted to 7.2) and c) ALA + PEG + X e+ pH size distribution.

### C.2) ALA:AuNPs Administration

At baseline, the body weight of all experimental rabbits ranged from 2.2 to 2.4 kg. Over the course of the study, all of the animals gained weight, but no significant difference was observed at any time point. The final weight ranged from 2.4 to 3.4 kg. A comparison of serum lipids in the control and experimental groups (60 days) is shown in the table 2 shows increase in total cholesterol and low density lipoproteins concentrations in the blood with the 1% cholesterol diet. All of the rabbits completed the experimental process.

Previous studies indicate that several types of porphyrins, including PPIX, accumulate in significant amounts in rapidly growing tissues such as atheromatous plaques<sup>8,15</sup>, and in this case the increase in the blood PPIX emission follow the growth of the plaques<sup>20</sup>. Since ALA is a precursor in the heme biosynthesis pathway, ALA is converted to PPIX, which is fluorescent<sup>21</sup>, and thorough this mechanism it is possible to enhance the PPIX emission present in the blood upon ALA administration<sup>22</sup>. To evaluate the capability of ALA:AuNPsAuNPs (ALA +PEG +Xe and pH adjusted to 7.2) to convert to PPIX, ALA:AuNPs were orally administrated to the animals and porphyrins were extracted from the total blood. PPIX fluorescence was measured and results are shown in Figure 4. In this figure, the signal emission area, which was obtained by integrating the endogenous PPIX emission spectra from 550–750 nm, is plotted as a function of the studied groups, control group (CG), control group with ALA (CGALA), experimental group with ALA (EGALA) and experimental group with ALA:AuNPs (EGALAAu). In this case blood was collected 24 hours after ALA or ALA:AuNPs administration. Each point corresponds to the average of the signal from each studied group.

**Table 2.** Serum lipids. Normal control group: rabbits were fed a normal diet; experimental group: rabbits were fed a high-cholesterol-diet for 60 days. Data are presented as the mean  $\pm$  SEM, n = 4 for control group and 6 for experimental group. TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol and glucose.

	CG	CG (Er $\pm$ )	EG (60 days)	EG (Er $\pm$ )
TC (mg/dL)	76.18	6.82	1344.55	200.13
HDL (mg/dL)	28.34	1.75	23.87	1.94
LDL (mg/dL)	14.56	1.44	558.30	81.26
Glucose (mg/dL)	106.77	8.54	167.87	24.04

The results, shown in figure 4, have shown an increase in the PPIX fluorescence for the animals that received ALA in both the control and experimental groups. The fluorescence intensity increased almost 6.0 fold in the experimental group with ALA in comparison with the control group after 34 days and ~7.7 fold after 60 days. The two-tailed P values are equals 0.0228 for 34 days and 0.0005 for 60 days. By conventional criteria, these differences are considered to be statistically significant. An increase in the PPIX fluorescence was also observed after oral ALA:AuNPs administration: ~2 fold in the experimental group with ALA in comparison with the control group after 34 days and ~3.7 fold after 60 days. For 34 days the two-tailed P value equals 0.3293. By conventional criteria, this difference is considered to be not statistically significant. For 60 days the two-tailed P value equals 0.0438. By conventional criteria, this difference is considered to be statistically significant. The sample sizes used in all experiments show analytical power >0.9, except for 34 days (CG x EGALAAu). In this case the number of animal is not sufficient to yield statistical significance (typically 12 animals per group are needed).

The results show that the functionalized gold nanoparticles reached atheromatous plaques and its ALA was converted to PPIX. The selective accumulation of PPIX in plaques provides a contrast between control animals and those with atherosclerosis.

**Figure 4.** Differences observed in the PPIX fluorescence in blood collected 34 and 60 days after diet procedure beginning from the control and experimental groups before and after 24 hs of ALA and ALA:AuNPs administration. Comparing with control group the two-tailed P values are equals 0.0228 for 34 days and 0.0005 for 60 days for ALA group. For EGALAAu group for 34 days the difference is considered to be not statistically significant and for 60 days the two-tailed P value equals 0.0438.

The extraction of porphyrin from the animal feces (coproporphyrin) collected 33 days after the diet procedure started was also measured and the results are shown in figure 5. In this case porphyrin was extracted before, 24 and 48 hs after ALA and ALA:AuNPs administration. The results show an increase in the porphyrin fluorescence for the three groups after 24 hours, indicating the elimination of porphyrin from the body. Probably the metabolism is faster in the presence of gold nanoparticles. This fact must explain why AuNPs produce an enhanced coproporphyrin fluorescence in feces at 24 hr. Comparisons between the averaged intensities for CGALA with EGALA and CGALA with EGALAAu were done. The two-tailed P value found was 0.2856 for EGALA and less than 0.0001 for EGALAAu. By conventional criteria, the difference observed for EGALAAu is considered to be extremely statistically significant. In this case the sample size used show analytical power > 0.9. In the comparisons with EGALA the number of animal is not sufficient to yield statistical significance (typically 12 animals per group are needed).

**Figure 5.** Differences observed in the copoporphyrin fluorescence in feces collected 33 days after diet procedure beginning from the control and experimental groups before and after 24 hs and 48 hs of ALA and ALA:AuNPs administration. Considering data for 24 hours, two-tailed P value found was 0.2856 for EGALA compared with CGALA group (not significant) and less than 0.0001 for EGALAAu compared with CGALA group.

Figure 6 shows the images obtained from aortas for the control and experimental groups. As can be observed in figure 6a, the

aorta of a control group rabbit (normal diet) has normal thickness, and no lipid is present in the intima layer. For experimental group rabbits (high cholesterol diets) the intima layer is thickened (figure 6b). All animals from the experimental group presented an increase in the arterial thickness after 60 days (from ~300 to ~900  $\mu\text{m}$ ). In the figure 6b a considerable foamy cell infiltration, and extracellular lipid accumulation are seen. No visible alteration was observed due to the presence of gold nanoparticles. Kidneys, lungs and liver tissues also maintain the same aspects for the animal from the EGALA and EGALAAu groups.

**Figure 6.** Microscopic appearance of atherosclerotic lesions of rabbits aortic arch. a) Control Group. b) Experimental Group (EGALAAuNPs) 100x. The artery shows thickening of the intima and arterial media. The thickest sections of the arteries show considerable foamy cell infiltration and extracellular lipid accumulation.

It is our understanding that this is the first study that analyses porphyrin accumulation in the blood and feces of animals with atherosclerosis after oral ALA:AuNPs administration. The PPIX accumulated in atheroma plaques is transferred to blood and feces and can be analyzed by porphyrin extraction. As the excess of heme and PPIX is harmful to the organism, it needs to be eliminated. In general, the porphyrin fraction of the hemoglobin molecule is released into the blood and later secreted by the liver in bile<sup>23</sup>. However, in atherosclerotic animals, the higher concentration of porphyrin is also excreted by feces.

## D. Conclusions

An increase in the blood and feces porphyrin emission after ALA:AuNPs administration suggests that ALA was incorporated by the gold nanoparticles, its structure was preserved, and a rapid conversion into endogenous porphyrins occurred, overloading the synthetic pathway that lead to the PPIX accumulation. The high accumulation of PPIX in tissues is thought to be the result of uncontrolled cell proliferation that accompanied the growth of atheromatous plaques. This finding indicated that ALA:AuNPs can aid in the early diagnosis and therapy of atherosclerosis with high sensitivity.

Other important characteristic about ALA:AuNPs is its high stability. This fact facilitates the drug administration since normally ALA must be prepared freshly and its pH adjusted.

The results indicate three clinical approaches for ALA:AuNPs administration:

- 1) Porphyrin blood and feces screening;
- 2) Diagnosis by contrast methods as computed tomography, magnetic resonance tomography, positron emission tomography, fluorescence angiography.
- Diagnosis by noninvasive methods as diffusion reflection is also possible;
- 3) Therapy using PDT, sonodynamic or photothermia.

Larger and better designed studies are being developed to elaborate more on this matter, to verify the most appropriate concentration of ALA:AuNPs solution and the best time for administration in animals.

## Acknowledgements

This work was supported by the “Fundação de Amparo a Pesquisa do Estado de São Paulo” (FAPESP), Grant number 2010/016544-1. The authors also would like to thank Maira Franco de Andrade for help in veterinary procedures.

## Notes

<sup>a</sup> Universidade Federal de São Paulo, Laboratório de Lasers e Óptica Biomédica Aplicada (LOBA) Instituto de Ciências Ambientais, Químicas e Farmacêuticas (ICAQF), Departamento de Ciências Exatas e da Terra (DCET), Rua Artur Riedel, 275 Eldorado, 09972-270 - Diadema, SP – Brazil, Fax: 551140436428; E-mail: lccourrol@gmail.com

<sup>b</sup> Instituto de Pesquisas Energéticas e Nucleares, Centro de Lasers e Aplicações, São Paulo, SP, Brazil.

<sup>c</sup> Instituto de Pesquisas Energéticas e Nucleares, Centro de Ciência e Tecnologia de Materias, São Paulo, SP, Brazil.

## References

1. P. Libby, P. M. Ridker and G. K. Hansson, *Nature*, 2011, **473**, 317-325.
2. J. S. Ross, N. E. Stagliano, M. J. Donovan, R. E. Breitbart and G. S. Ginsburg, *Atherosclerosis* *Vi*, 2001, **947**, 271-293.
3. X.-F. Li, C.-Y. Chen, Y.-H. Zhao and X.-Y. Yuan, *Progress in Biochemistry and Biophysics*, 2014, **41**, 739-748.
4. T. Curry, R. Kopelman, M. Shilo and R. Popovtzer, *Contrast Media & Molecular Imaging*, 2014, **9**, 53-61.
5. V. Sanna, N. Pala and M. Sechi, *International Journal of Nanomedicine*, 2014, **9**, 467-483.
6. D. Fixler, *SPIE Optical Fibers and Sensors for Medical Diagnostics and Treatment Applications Xiv*, 2014, **8938**.
7. J. Xie, S. Lee and X. Chen, *Advanced Drug Delivery Reviews*, 2010, **62**, 1064-1079.
8. C. H. Peng, Y. S. Li, H. J. Liang, J. L. Cheng, Q. S. Li, X. Sun, Z. T. Li, F. P. Wang, Y. Y. Guo, Z. Tian, L. M. Yang, Y. Tian, Z. G. Zhang and W. W. Cao, *Journal of Photochemistry and Photobiology B-Biology*, 2011, **102**, 26-31.
9. R. Waksman, P. E. McEwan, T. I. Moore, R. Pakala, F. D. Kolodgie, D. G. Hellinga, R. C. Seabron, S. J. Rychnovsky, J. Vasek, R. W. Scott and R. Virmani, *Journal of the American College of Cardiology*, 2008, **52**, 1024-1032.
10. Y. Murayama, Y. Harada, K. Imaizumi, P. Dai, K. Nakano, K. Okamoto, E. Otsuji and T. Takamatsu, *International Journal of Cancer*, 2009, **125**, 2256-2263.
11. M. Benito, V. Martin, M. D. Blanco, J. M. Teijon and C. Gomez, *Journal of Pharmaceutical Sciences*, 2013, **102**, 2760-2769.
12. C. P. Yao, S. J. Wang, Y. Yang, Y. L. Han, H. Xu, W. H. Zeng and Z. X. Zhang, *Spectroscopy and Spectral Analysis*, 2012, **32**, 2519-2522.
13. J. L. Cheng, X. Sun, S. Y. Guo, W. Cao, H. B. Chen, Y. H. Jin, B. Li, Q. N. Li, H. Wang, Z. Wang, Q. Zhou, P. Wang, Z. G. Zhang, W. W. Cao and Y. Tian, *International Journal of Nanomedicine*, 2013, **8**, 669-676.
14. F. P. Wang, Q. P. Gao, S. Y. Guo, J. L. Cheng, X. Sun, Q. N. Li, T. Y. Wang, Z. G. Zhang, W. W. Cao and Y. Tian, *Biomed Research International*, 2013.
15. S. Y. Guo, X. Sun, J. L. Cheng, H. B. Xu, J. H. Dan, J. Shen, Q. Zhou, Y. Zhang, L. L. Meng, W. W. Cao and Y. Tian, *International Journal of Nanomedicine*, 2013, **8**, 2239-2246.
16. S. Olejnik and J. Algina, *Contemporary Educational Psychology*, 2000, **25**, 241-286.
17. C. W. Chung, K. D. Chung, Y. I. Jeong and D. H. Kang, *International Journal of Nanomedicine*, 2013, **8**, 809-819.
18. W. Hou and S. B. Cronin, *Advanced Functional Materials*, 2013, **23**, 1612-1619.
19. M. Sakamoto, M. Fujistuka and T. Majima, *Journal of Photochemistry and Photobiology C-Photochemistry Reviews*, 2009, **10**, 33-56.
20. M. Nascimento da Silva, L. B. Sicchieri, F. Rodrigues de Oliveira Silva, M. F. Andrade and L. C. Courrol, *Analyst*, 2014, **139**, 1383-1388.
21. L. C. Courrol, F. R. de Oliveira Silva, E. L. Coutinho, M. F. Piccoli, R. D. Mansano, N. D. Vieira Junior, N. Schor and M. H. Bellini, *Journal of Fluorescence*, 2007, **17**, 289-292.
22. F. R. de Oliveira Silva, M. H. Bellini, C. T. Nabeshima, N. Schor, N. D. Vieira, Jr. and L. C. Courrol, *Photodiagnosis and Photodynamic Therapy*, 2011, **8**, 7-13.
23. M. L. Welcker, *New England Journal of Medicine*, 1945, **232**, 11-19.






Figure 1. Optical absorption spectra of gold nanoparticles formed with illumination by a Xe lamp. ALA, ALA+PEG ( $\text{HAuCl}_4 = 0,02074\text{g} + \text{ALA} = 0,08332\text{ g} + \text{PEG} = 0,02844\text{ g}$  in 200 ml Mili-Q  $\text{H}_2\text{O}$ ); ALANPs+PEG+Xe (ALA+PEG and 2 minutes of Xe light irradiation); ALANPs+PEG+Xe+pH (ALA+PEG +Xe and pH of solution adjusted to 7.2).




**Figure 2.** Color of a gold colloidal suspension a) before (left) and after (right) illumination with white light from a Xe-lamp for 1 minute and b) after change pH from ~3.0 to 7.0.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 3.** TEM images of synthesized ALA:AuNPs: a) ALA+PEG+Xe ( $\text{HAuCl}_4 = 0,02074\text{g} + \text{ALA} = 0,08332\text{ g} + \text{PEG} = 0,02844\text{ g}$  in 200 ml Mili-Q  $\text{H}_2\text{O}$  and 2 minutes of Xe lighth irradiation); b) ALA + PEG + Xe + pH (ALA + PEG + Xe and pH of solution adjusted to 7.2) and c) ALA + PEG + X e+ pH size distribution.



**Figure 4.** Differences observed in the PPIX fluorescence in blood collected 34 and 60 days after diet procedure beginning from the control and experimental groups before and after 24 hs of ALA and ALA:AuNPs administration. Comparing with control group the two-tailed P values are equals 0.0228 for 34 days and 0.0005 for 60 days for ALA group. For EGALAAu group for 34 days the difference is considered to be not statistically significant and for 60 days the two-tailed P value equals 0.0438.



**Figure 5.** Differences observed in the coproporphyrin fluorescence in feces collected 33 days after diet procedure beginning from the control and experimental groups before and after 24 hs and 48 hs of ALA and ALA:AuNPs administration. Considering data for 24 hours, two-tailed P value found was 0.2856 for EGALA compared with CGALA group (not significant) and less than 0.0001 for EGALAAu compared with CGALA group.



**Figure 6.** Microscopic appearance of atherosclerotic lesions of rabbits aortic arch. a) Control Group. b) Experimental Group (EGALAAuNPs) 100x. The artery shows thickening of the intima and arterial media. The thickest sections of the arteries show considerable foamy cell infiltration and extracellular lipid accumulation.